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Abstract: BACKGROUND Transcatheter mitral valve replacement (TMVR) may mature to become a
therapeutic option for high-risk patients with severe mitral regurgitation (MR), particularly in patients
at high or prohibitive surgical risk. MR patients with preexisting aortic valve prosthesis have been
excluded from most TMVR trials because of the potential risks of left ventricular outflow tract obstruction
or interaction between the TMVR anchoring mechanism and the aortic prosthesis. We describe the
procedural and short-term outcomes of transapical TMVR with the Tiara valve in patients experiencing
severe symptomatic MR with previous aortic valve replacement (AVR). METHODS AND RESULTS
Twelve consecutive high surgical risk patients (11 men; mean age, 75±6 years) with aortic valve prosthesis
and severe MR underwent TMVR with Tiara valve. Aortic valves were mechanical in 5 and biological in
7 patients, while 1 patient had previously undergone implantation of a transcatheter valve within a failed
bioprosthetic surgical valve. Six patients (50%) had undergone redo surgical aortic valve replacement.
Clinical characteristics of the group include prior mitral valve repair in 2, prior coronary bypass grafting
surgery in 5, chronic atrial fibrillation in 7, renal failure in 9, and pacemaker/cardiac resynchronization
device in 9 patients. Mean Society of Thoracic Surgery score and EuroSCORE II were 10.5±4.4 and
12.4±3.7, respectively. Mean baseline left ventricular ejection fraction was 35.5±5.3% (range, 30%-
45%). The Tiara valve was implanted uneventfully in all patients. Device migration or left ventricular
outflow tract obstruction was not observed. No patient required conversion to open heart surgery or
periprocedural hemodynamic support. Procedural success was 100% with no death, MI, stroke, major
bleeding, or access site complications at 30 days. MR was eliminated in all 12 patients immediately after
implantation. CONCLUSIONS Transapical mitral valve replacement with the Tiara valve in high-risk
patients with severe MR and aortic valve prostheses is technically feasible and can be performed safely.
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BACKGROUND: Transcatheter mitral valve replacement (TMVR) may 
mature to become a therapeutic option for high-risk patients with severe 
mitral regurgitation (MR), particularly in patients at high or prohibitive 
surgical risk. MR patients with preexisting aortic valve prosthesis have 
been excluded from most TMVR trials because of the potential risks of 
left ventricular outflow tract obstruction or interaction between the 
TMVR anchoring mechanism and the aortic prosthesis. We describe the 
procedural and short-term outcomes of transapical TMVR with the Tiara 
valve in patients experiencing severe symptomatic MR with previous aortic 
valve replacement (AVR).
METHODS AND RESULTS: Twelve consecutive high surgical risk patients 
(11 men; mean age, 75±6 years) with aortic valve prosthesis and severe 
MR underwent TMVR with Tiara valve. Aortic valves were mechanical in 
5 and biological in 7 patients, while 1 patient had previously undergone 
implantation of a transcatheter valve within a failed bioprosthetic 
surgical valve. Six patients (50%) had undergone redo surgical aortic 
valve replacement. Clinical characteristics of the group include prior 
mitral valve repair in 2, prior coronary bypass grafting surgery in 5, 
chronic atrial fibrillation in 7, renal failure in 9, and pacemaker/cardiac 
resynchronization device in 9 patients. Mean Society of Thoracic Surgery 
score and EuroSCORE II were 10.5±4.4 and 12.4±3.7, respectively. Mean 
baseline left ventricular ejection fraction was 35.5±5.3% (range, 30%–
45%). The Tiara valve was implanted uneventfully in all patients. Device 
migration or left ventricular outflow tract obstruction was not observed. 
No patient required conversion to open heart surgery or periprocedural 
hemodynamic support. Procedural success was 100% with no death, MI, 
stroke, major bleeding, or access site complications at 30 days. MR was 
eliminated in all 12 patients immediately after implantation.
CONCLUSIONS: Transapical mitral valve replacement with the Tiara 
valve in high-risk patients with severe MR and aortic valve prostheses is 
technically feasible and can be performed safely.
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With the ongoing technological advancement in the field of transcatheter mitral valve replacement (TMVR), it is expected that 
TMVR will eventually become an alternative treatment 
to mitral valve (MV) surgery for patients with severe 
mitral regurgitation (MR). Compared with transcath-
eter aortic valve replacement (AVR), TMVR seems to 
be more complex and more challenging. Among the 
challenges TMVR technology faces are the asymmetri-
cal annulus, the irregular geometry of MV leaflets, the 
large dimensions, the high-pressure gradient across the 
MV (closing pressure), the absence of a calcific structure 
for anchoring, the complex subvalvular anatomy, and 
the risk of left ventricular outflow tract (LVOT) obstruc-
tion.1 LVOT obstruction is described not only after 
TMVR2,3 but also after mitral surgery with annuloplasty 
rings and prostheses, where it may lead to catastrophic 
outcomes.4–6 The risk of LVOT obstruction after TMVR 
may be higher in patients with preexisting aortic valve 
prosthesis because patients with prior aortic stenosis 
often have left ventricular (LV) hypertrophy and small 
LV cavity, and the frame of the aortic prosthesis can 
extend into the LVOT.
In addition, the anchoring mechanism of TMVR may 
interfere with the proper functioning of an aortic pros-
thesis, especially a mechanical valve. Consequently, 
aortic prostheses have been considered a relative con-
traindication to TMVR in these patients.
The Tiara TMVR device (Neovasc, Inc, Richmond, 
Canada)—a transcatheter mitral bioprosthesis—was 
designed to fit the asymmetrical and multiplanar mitral 
annulus. It is fabricated using cross-linked bovine pericar-
dial tissue leaflets mounted inside a self-expanding nitinol 
frame, which can be crimped onto a short, sheathless 
transapical delivery system. The D-shaped Tiara valve is 
designed to match the natural orifice of the MV, avoiding 
impingement of the LVOT and to prevent any interfer-
ence with the aortic valve or prosthesis (Figure 1).7–11
The Tiara valve is currently being evaluated in 2 
ongoing clinical trials: TIARA-I—an early feasibility 
trial in the United States, Canada, and Belgium—and 
TIARA-II—a European Conformité Européenne Mark 
Trial in Germany, Italy, and the United Kingdom. In 
addition, patients have also been treated under com-
passionate programs in Canada, Italy, Germany, Israel, 
and Switzerland.
In this retrospective analysis, we describe, for the first 
time, the periprocedural and short-term outcomes of 
patients with severe MR and previous AVR treated with 
the Tiara TMVR system. We show that with an effective 
patient screening, and a valve design that fits into the 
native mitral apparatus, LVOT obstruction is avoided.
METHODS
The data, analytic methods, and study materials will not be 
made available to other researchers for purposes of reproduc-
ing the results or replicating the procedure.
Patients
This is a retrospective analysis of the baseline, periprocedural, 
and ≤30-day postprocedural data, collected on 12 consecu-
tive patients with previous surgical AVR who underwent TMVR 
using the Tiara system. All implant procedures were approved 
by the institutional and national clinical research committees.
Eligibility for Tiara implantation was determined by a cen-
tral screening committee after evaluating the relevant clinical 
data for each patient, and the core laboratories analyses of 
the echocardiographic studies (TTE and TEE), and computed 
tomography (CT).
Imaging
Echocardiographic eligibility criteria were severe symptomatic 
MR (stage D) by 2014 American Heart Association/American 
College of Cardiology Valvular Heart Disease Guidelines clas-
sification, as determined by the Echo Core Laboratory, as well 
as anatomic eligibility criteria for the 2 available sizes of the 
Tiara mitral bioprosthesis.
Contrast-enhanced gated CT data acquisition of the entire 
cardiac cycle was used for the preprocedural analyses of the 
mitral annulus, subvalvular complex, LV, LVOT, and aortic pros-
thesis.12,13 CT data including the entire rib cage were used to 
determine the optimal intercostal space for transapical access.
Anatomic eligibility criteria as determined by the CT 
included the following:
Mitral annulus area and perimeter to fit the available Tiara 
sizes; the degree of potential contact between the prosthetic 
valve tabs and the LV walls; and the potential risk for LVOT 
obstruction, which was virtually assessed by simulating the 
implanted device into the CT dataset with subsequent pla-
nimetry of the anticipated neo-LVOT cross-sectional area. 
WHAT IS KNOWN
• Mitral regurgitation is under-referred and 
undertreated.
• Transcatheter mitral valve interventions, including 
repair and replacement, are potential options for 
high-risk surgical mitral regurgitation patients.
• Transcatheter mitral valve replacement is contra-
indicated in patients with previous aortic valve 
replacement because of the potential interac-
tion of the transcatheter mitral valve replacement 
device with the aortic prosthesis.
WHAT THE STUDY ADDS
• Transcatheter mitral valve replacement with the 
Tiara device is safe and effective in treating patients 
with symptomatic mitral regurgitation.
• Transcatheter mitral valve replacement with the 
Tiara device in patients with an existing aortic 
prosthesis can be performed safely.
• Excellent clinical and hemodynamic outcomes 
were seen.
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Only patients with predicted neo-LVOT area of ≥2.0 cm2 at 
end systole were considered eligible for treatment14 (Figure 2).
Procedure
Tiara implantations were performed under general anesthesia 
via a transapical approach under TEE and fluoroscopic guid-
ance. Through a left mini-thoracotomy, a needle puncture 
was performed and a J-tip wire introduced across the MV 
and into the left atrium. The Tiara TMVR delivery system was 
introduced directly over the wire across the MV, and the atrial 
portion of the prosthesis was unsheathed, properly oriented, 
and aligned with the native D-shaped mitral annulus. The 
delivery system and the valve were then pulled back to seat 
the atrial part of the valve onto the atrial aspect of the mitral 
annulus, and the ventricular anchors were then released to 
secure the valve before it was completely released on a beat-
ing heart. Echocardiographic evaluation of the anatomy of 
the heart, the performance of the prosthetic mitral and aortic 
valves, and the presence of LVOT gradient, were performed at 
the completion of the implantation procedure, before hospi-
tal discharge, and at 30 days.
End Points
The end points of our study were the occurrence of ≥1 of the 
following adverse events post-Tiara implantation: periproce-
dural and ≤30-day death, MI, stroke, and major bleeding; the 
need to convert to an open chest surgery; the need for a cardio-
pulmonary support system; the occurrence of a device migra-
tion; postimplantation (>trivial) MR or paravalvular leak; and 
the presence of hemodynamically significant LVOT gradient.
Statistical Analysis
Continuous variables are expressed as mean±SD, and cat-
egorical variables are expressed as n (%). Data analyses were 
performed using the Statistical Package for Social Sciences 
(SPSS), version 24 (IBM, Inc, Chicago, IL).
RESULTS
From 2015 to 2017, 12 consecutive patients with severe 
symptomatic MR, as determined by the Echo Core 
Laboratory and the Central Screening Committee, and 
Figure 1. Virtual implant of a 35mm Tiara device into a patient with previous mechanical aortic valve replacement, showing non-obstructive left 
ventricular outflow tract. 
Top, The Tiara valve is anatomically shaped to fit the asymmetrical, D-shaped mitral annulus. Currently, there are 2 valve sizes available, 35 mm and 40 mm, and 
the delivery catheter is 32F and 36F accordingly. The atrial portion of the valve is designed to fit the atrial portion of the mitral annulus. Ventricular anchoring 
structures are designed to secure the valve onto the fibrous trigones and posterior shelf of the sub-annulus. The delivery device comprises a self-dilating tip with 
a single turn-knob mechanism to allow controlled deployment and is designed to directly enter the left ventricular apex without a delivery introducer sheath. 
Bottom, Atrial view of the D-shaped Tiara in its open and closed positions.
Figure 2. Preoperative computed tomog-
raphy (CT) with cloning a simulated 
device-specific contour into the CT image, 
demonstrating virtual Tiara implantation.  
Demonstrated proper anatomic fit, 
unobstructed left ventricular outflow tract 
(LVOT) and lack of interaction with a mechanical 
aortic valve (left), and measurement of the 
predicted neo-LVOT area in the short-axis view 
(right).
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previous AVR were treated with transapical implanta-
tion of the Tiara bioprosthetic valve. All were consid-
ered high surgical and prohibitive risk and unsuitable for 
alternative approved mitral repair or replacement proce-
dures by the local heart team. TMVRs were performed 
either under compassionate use programs or as part of 
the TIARA-I early feasibility clinical trial. Two additional 
Tiara candidates with previous AVR were excluded. One 
because of likelihood of interference with the prosthetic 
aortic valve and a high degree of potential septal con-
tact and a small neo-LVOT, and the second candidate 
was excluded because of potential for long-term inter-
action with a low-placed aortic bioprosthesis. Among all 
the other patients who were considered as screen failure 
for Tiara, previous AVR and potential LVOT obstruction 
was not the reason of exclusion.
All 12 patients had at least 1 previous surgical AVR. 
Among this group, 5 had mechanical aortic prosthe-
sis, 7 had aortic bioprosthesis, and 1 had transcatheter 
aortic valve in valve implantation. Six of the patients 
had a history of at least 2 previous AVR surgeries, 1 
patient had aortic root replacement, 2 patients had MV 
repair, and 5 had prior coronary bypass grafting surgery. 
A summary of the patients’ clinical characteristics and 
their estimated surgical risk is presented in Table 1.
In all patients, the predicted post-TMVR LVOT area as 
determined by CTA at 70% systole was >2.0 cm2.
The MR pathogenesis was functional (secondary) in 6, 
primary/degenerative in 2, including 1 patient with rheu-
matic MV disease, and mixed pathogenesis in 4 patients.
Baseline mitral annulus area and circumference were 
in the range of 6.6 to 12.5 cm2 and 9 to 13 cm, respec-
tively, as measured by CTA. All 12 transapical Tiara implan-
tations were completed successfully and uneventfully, 
with optimal alignment and anchoring of the D-shaped 
prosthetic Tiara valves. There was no conversion to open 
heart surgery or need for mechanical hemodynamic sup-
port. MR was eliminated immediately post-implantation, 
and the degree of MR at predischarge and at 30-day fol-
low-up echo was none or trace. Procedural success and 
device success rates were 100%. There were no cases of 
periprocedural and 30-day mortality, MI, stroke, bleed-
ing, or need for pacemaker implantation.
Table 1. Patient Demographics
  Range
Male sex 11 (92%)  
Mean age, y 75±6 68–82
Aortic surgical valve replacement 12  
  Mechanical prosthesis 5 (42%)  
  Bioprosthesis 7 (58%)  
  Aortic valve in valve 1 (8%)  
  Prior MV repair (ring) 2 (17%)  
Prior CABG surgery 5 (42%)  
Chronic atrial fibrillation 7 (58%)  
Pacemaker/ICD/CRTD 9 (75%)  
Chronic kidney disease (eGFR<45) 9 (75%)  
Mean STS risk score, % 10.5±4.4 4.3–18.5
Mean EuroSCORE II, % 12.4±3.7 7.8–18.0
Mean baseline LVEF, % 35.5±5% 30%–45%
Mean systolic pulmonary artery 
pressure, mm Hg
58±22 27–107
NYHA class II 1  
NYHA class III 10  
NYHA class IV 1  
CABG indicates coronary bypass grafting; CRTD, cardiac resynchronization 
device; eGFR, glomerular filtration rate; ICD, internal cardiac defibrillator; LVEF, 
left ventricular ejection fraction; MV, mitral valve; NYHA, New York Heart 
Association; and STS, Society of Thoracic Surgery.
Table 2. Procedural and Periprocedural Outcomes
Procedural success 12 (100%)
Periprocedural and 30-d death/stroke/MI/bleeding 0
Conversion to open chest surgery 0
Cardiopulmonary support 0
Device migration 0
LVOT obstruction 0
Interference with aortic prosthesis 0
Postprocedural MR >trivial 0
Postprocedural paravalvular leak 0
Access site complication 0
Postprocedural pacemaker implantation 0
LVOT indicates left ventricular outflow tract; MI, myocardial infarction; and 
MR, mitral regurgitation.
Figure 3. Profile and enface views of postimplant computed tomogra-
phy of a Tiara valve in a patient with preexisting Carpentier-Edwards 
Perimount bioprosthesis.
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Baseline LVOT pressure gradient was measured at 
the beginning of each procedure. No pressure gradient 
was measured in any of the 12 patients. There was no 
LVOT gradient measured by echo and by direct catheter 
measurement in any of the patients. There was no valve 
malposition or valve migration detected by postproce-
dural or predischarge and 30-day echo (Table 2).
Preprocedural factors, such as MR pathogenesis (pri-
mary, secondary, or mixed), type of aortic prosthesis 
(mechanical or biological), number of previous AVR sur-
geries or other heart surgeries, and previous MV repair 
surgery, did not influence procedural success, duration, 
or complexity of the procedure.
No interactions between the aortic prostheses and 
the Tiara valve during the implantation procedure or at 
follow-up were noted in any of the patients (Figures 2 
through 4).
DISCUSSION
This is the first description of periprocedural and short-
term outcomes of TMVR in patients with previous surgi-
cal AVR. In this retrospective analysis, we describe, for 
the first time, the periprocedural and short-term out-
comes of patients with severe MR and previous AVR 
treated with the Tiara TMVR system. We show that 
with an effective patient screening, and a valve design 
that fits into the native mitral apparatus, LVOT obstruc-
tion is avoided and that preexisting aortic prosthesis 
does not add any complexity to the TMVR procedure 
or to its results.
The development of TMVR therapy for MR has been 
slow and challenging because of the complex anatomy 
and the great heterogenic pathogenesis of the MR.
The field of TMVR is only in its first steps of develop-
ment, and the rate of its evolution into a practical and 
established interventional procedure, mature enough 
to treat patients, will be much slower than that of 
TAVR. Data published and presented by the different 
groups of researchers on various aspects of their TMVR 
experience can facilitate the fruition of the TMVR field.
The unique features and complex anatomy of 
the native mitral apparatus require a complex device 
design.1,15 TMVR device must fit into the multiplanar 
and asymmetrical native mitral apparatus, achieve 
good apposition and anchoring to the dynamic move-
ment of the mitral annulus, bear the high LV systolic 
closing gradient, and effectively seal and prevent para-
valvular leak. Unlike transcatheter aortic valves, most 
MV implantations are performed in the absence of sig-
nificant annular calcification. This limits the amount of 
radial force the mitral prosthesis can apply to achieve 
adequate fixation without altering the shape of the 
native mitral annulus and the anatomy of the base of 
the heart. Furthermore, protrusion of the bulky frame of 
the valve into the LV may cause LVOT obstruction, inter-
fere with the function of a native or prosthetic aortic 
valve, interact with the anterior MV leaflet, and poten-
tially cause systolic anterior motion. The anatomy of the 
LVOT exhibits significant interindividual variability and is 
influenced mainly by the configuration of the intraven-
tricular septum, LV size, and aortomitral angulation.14,16
Figure 4. Images of Tiara implant in a 
patient with a Medtronic Hall mechanical 
aortic valve.  
A, Postprocedural cineangiography. B, 
3-dimensional postprocedural echo of the Tiara 
and the bileaflet mechanical aortic valve. C, 
30-d postprocedure computed tomography.
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The coexistence of aortic valve disease, and especially 
the presence of a prosthetic aortic valve, might add an 
additional component of complexity to the challenging 
TMVR procedure with possible increased risk. At present, 
some evolving TMVR technologies are excluding patients 
with preexisting aortic prosthesis from their studies.
The Tiara valve assembly is asymmetrical and shaped 
to match the natural geometry of the native mitral appa-
ratus and to prevent impingement of the aorta or LVOT. 
The anchoring and fixation of the device does not rely 
solely on radial force, and by design, the D-shaped valve 
is sparing the LVOT. The ventricular portion of the device 
expands within the subannular space of the LV to draw 
the native anatomy, as well as the anterior mitral leaflet 
against the body of the valve to prevent paravalvular 
leak and LVOT obstruction by systolic anterior motion.
Here, we demonstrate that the presence of a pros-
thetic aortic valve, either mechanical or biological, did 
not add any extra complexity to the procedure. On the 
contrary, the presence of the prosthetic valve added a 
helpful fluoroscopic marker, which further assists with 
the process of device alignment.
In conclusion, TMVR with the Tiara valve in patients 
with preexisting aortic valve prosthesis was safely and 
successfully implanted and was not associated with LVOT 
obstruction or with any other mechanical or hemodynamic 
interference. The design of this device affords a stable and 
predictable implantation, representing a reasonable alter-
native to treat this particular subset of patients.
ARTICLE INFORMATION
Received January 9, 2018; accepted August 11, 2018.
Correspondence
Anson Cheung, MD, St. Paul’s Hospital, University of British Columbia, 1081 
Burrard St, Vancouver, BC, Canada V6Z 1Y6. Email acheung@providence-
health.bc.ca
Affiliations
St. Paul’s Hospital, University of British Columbia, Vancouver, Canada (A.C., 
J.W., R.M., P.B.). Universitäres Herzzentrum, Hamburg, Germany (U.S., F.G.D., 
L.C.). IRCCS San Raffaele Scientific Institute, Milan, Italy (P.D., A.L.). London 
Health Sciences Centre, Ontario, Canada (B.K., R.B.). Cardiocentro Ticino, 
Lugano, Switzerland (E.F., M.M., L.B.). Tel Aviv Medical Center, Sackler School 
of Medicine, Tel Aviv University, Israel (Y.B.-G., S.B.).
Disclosures
Dr Cheung serves as a consultant at Neovasc, Inc, and as a principal investiga-
tor for TIARA-I Early Feasibility Trial. Dr Banai serves as a medical director at 
Neovasc, Inc. Dr Blanke provides core lab services for Neovasc for which he 
receives no direct compensation and is a consultant to Neovasc. Drs Denti and 
Deuschl are a consultant to Neovasc, Inc. The other authors report no conflicts.
REFERENCES
 1. Regueiro A, Granada JF, Dagenais F, Rodés-Cabau J. Transcatheter 
mitral valve replacement: insights from early clinical experience and 
future challenges. J Am Coll Cardiol. 2017;69:2175–2192. doi: 
10.1016/j.jacc.2017.02.045
 2. Guerrero M, Dvir D, Himbert D, Urena M, Eleid M, Wang DD, Greenbaum A, 
Mahadevan VS, Holzhey D, O’Hair D, Dumonteil N, Rodés-Cabau J, Piazza 
N, Palma JH, DeLago A, Ferrari E, Witkowski A, Wendler O, Kornowski 
R, Martinez-Clark P, Ciaburri D, Shemin R, Alnasser S, McAllister D, Bena 
M, Kerendi F, Pavlides G, Sobrinho JJ, Attizzani GF, George I, Nickenig G, 
Fassa AA, Cribier A, Bapat V, Feldman T, Rihal C, Vahanian A, Webb J, 
O’Neill W. Transcatheter mitral valve replacement in native mitral valve 
disease with severe mitral annular calcification: results from the first mul-
ticenter global registry. JACC Cardiovasc Interv. 2016;9:1361–1371. doi: 
10.1016/j.jcin.2016.04.022
 3. Paradis JM, Del Trigo M, Puri R, Rodés-Cabau J. Transcatheter valve-
in-valve and valve-in-ring for treating aortic and mitral surgical pros-
thetic dysfunction. J Am Coll Cardiol. 2015;66:2019–2037. doi: 
10.1016/j.jacc.2015.09.015
 4. Rosendal C, Hien MD, Bruckner T, Martin EO, Szabo G, Rauch H. Left ven-
tricular outflow tract: intraoperative measurement and changes caused 
by mitral valve surgery. J Am Soc Echocardiogr. 2012;25:166–172. doi: 
10.1016/j.echo.2011.10.008
 5. Wu Q, Zhang L, Zhu R. Obstruction of left ventricular outflow tract after 
mechanical mitral valve replacement. Ann Thorac Surg. 2008;85:1789–
1791. doi: 10.1016/j.athoracsur.2007.11.069
 6. Duncan A, Daqa A, Yeh J, Davies S, Uebing A, Quarto C, Moat N. 
Transcatheter mitral valve replacement: long-term outcomes of first-
in-man experience with an apically tethered device- a case series 
from a single centre. EuroIntervention. 2017;13:e1047–e1057. doi: 
10.4244/EIJ-D-17-00154
 7. Banai S, Jolicoeur EM, Schwartz M, Garceau P, Biner S, Tanguay JF, 
Cartier R, Verheye S, White CJ, Edelman E. Tiara: a novel catheter-
based mitral valve bioprosthesis: initial experiments and short-term 
pre-clinical results. J Am Coll Cardiol. 2012;60:1430–1431. doi: 
10.1016/j.jacc.2012.05.047
 8. Banai S, Verheye S, Cheung A, Schwartz M, Marko A, Lane R, Jolicoeur 
EM, Garceau P, Biner S, Tanguay JF, Edelman ER, White CJ. Transapical 
mitral implantation of the Tiara bioprosthesis: pre-clinical results. JACC 
Cardiovasc Interv. 2014;7:154–162. doi: 10.1016/j.jcin.2013.10.009
 9. Cheung A, Stub D, Moss R, Boone RH, Leipsic J, Verheye S, Banai 
S, Webb J. Transcatheter mitral valve implantation with Tiara bio-
prosthesis. EuroIntervention. 2014;10(suppl U):U115–U119. doi: 
10.4244/EIJV10SUA17
 10. Cheung A, Webb J, Verheye S, Moss R, Boone R, Leipsic J, Ree R, Banai 
S. Short-term results of transapical transcatheter mitral valve implanta-
tion for mitral regurgitation. J Am Coll Cardiol. 2014;64:1814–1819. doi: 
10.1016/j.jacc.2014.06.1208
 11. Verheye S, Cheung A, Leon M, Banai S. The Tiara transcatheter mitral 
valve implantation system. EuroIntervention. 2015;11(suppl W):W71–
W72. doi: 10.4244/EIJV11SWA20
 12. Blanke P, Dvir D, Cheung A, Levine RA, Thompson C, Webb JG, Leipsic J. 
Mitral annular evaluation with CT in the context of transcatheter mitral 
valve replacement. JACC Cardiovasc Imaging. 2015;8:612–615. doi: 
10.1016/j.jcmg.2014.07.028
 13. Blanke P, Naoum C, Webb J, Dvir D, Hahn RT, Grayburn P, Moss RR, 
Reisman M, Piazza N, Leipsic J. Multimodality imaging in the context of 
transcatheter mitral valve replacement: establishing consensus among 
modalities and disciplines. JACC Cardiovasc Imaging. 2015;8:1191–1208. 
doi: 10.1016/j.jcmg.2015.08.004
 14. Blanke P, Naoum C, Dvir D, Bapat V, Ong K, Muller D, Cheung A, Ye 
J, Min JK, Piazza N, Theriault-Lauzier P, Webb J, Leipsic J. Predicting 
LVOT obstruction in transcatheter mitral valve implantation: concept 
of the Neo-LVOT. JACC Cardiovasc Imaging. 2017;10:482–485. doi: 
10.1016/j.jcmg.2016.01.005
 15. Maisano F, Alfieri O, Banai S, Buchbinder M, Colombo A, Falk V, Feldman 
T, Franzen O, Herrmann H, Kar S, Kuck KH, Lutter G, Mack M, Nickenig 
G, Piazza N, Reisman M, Ruiz CE, Schofer J, Søndergaard L, Stone GW, 
Taramasso M, Thomas M, Vahanian A, Webb J, Windecker S, Leon MB. 
The future of transcatheter mitral valve interventions: competitive or com-
plementary role of repair vs. replacement? Eur Heart J. 2015;36:1651–
1659. doi: 10.1093/eurheartj/ehv123
 16. Bapat V, Pirone F, Kapetanakis S, Rajani R, Niederer S. Factors influenc-
ing left ventricular outflow tract obstruction following a mitral valve-
in-valve or valve-in-ring procedure, part 1. Catheter Cardiovasc Interv. 
2015;86:747–760. doi: 10.1002/ccd.25928
D
ow
nloaded from
 http://ahajournals.org by on November 22, 2018
